MedTrace Logo

Evaluation of a Diet in Patients With Senile Dementia

NCT01192529 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 184

Last updated 2012-06-22

No results posted yet for this study

Summary

The most common symptoms associated to senile dementia disease are confusion about schedules, hyperactivity... In this sense, these patients have frequently poor nutrition, resulting in malnutrition problems or malnutrition high risk.

Conditions

Interventions

DIETARY_SUPPLEMENT

Supressi. T-Diet plus Range

Supressi is a complete high protein and moderated high energy oral nutrition supplement, indicated for the dietary management of patients with neurodegenerative diseases and related malnutrition. Experimental group patients will receive, 2 packs per day (Tetra brik aseptic)of 200 ml for 6 months.

DIETARY_SUPPLEMENT

High Protein. T-Diet plus Range

T-Diet plus High Protein is a complete high protein and moderated high energy oral nutrition supplement, indicated for the dietary management of patient with related malnutrition and with increased protein requirements.

Sponsors & Collaborators

  • Vegenat, S.A.

    lead INDUSTRY

Principal Investigators

  • Antonio J Pérez de la Cruz, MD PhD · Clinical Nutrition and Dietetic Unit, University Hospital Virgen de las Nieves

  • Ángel Gil Hernández, PhD · Department of Biochemistry and Molecular Biology II. University of Granada

  • Adrián Arés Luque, MD · Neurological Unit, Complejo Asistencial de León

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2012-09-30
Completion
2012-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01192529 on ClinicalTrials.gov